Market Outlook: Growth and Value Recovery Indian equity markets are showing significant resilience as of February 2026. The **Nifty 50** recently crossed the **25,800** mark, supported by strong domestic liquidity and a shift in interest toward sectors offering long-term stability. Pharmaceutical Sector: The Value Play The pharmaceutical industry is benefiting from a blend of government support and attractive valuations. The **Union Budget 2026-27** recently introduced the **Biopharma SHAKTI** initiative, aimed at scaling domestic manufacturing. **Sun Pharma** remains a core focus for investors, currently trading at approximately **₹1,704**. With a market capitalization exceeding **₹4 lakh crore**, it continues to dominate the domestic oncology and generic segments. Multinational corporations are also witnessing a revival. **GlaxoSmithKline (GSK) Pharmaceuticals** reported a robust **28.6%** jump in net profit to **₹295.6 crore** for the December quarter. **Pfizer India**, trading near **₹4,590**, maintains a steady outlook as analysts highlight its strong cash reserves and dividend potential. Speciality Chemicals: Patience for the Bottom The speciality chemicals sector is navigating a prolonged global downcycle, with production growth forecasts moderated to **2%** for 2026. However, India is positioned as a bright spot, with domestic chemical production projected to grow by **10.9%** this year. Earnings for the quarter have been mixed. For instance, **DCW Limited** expects a slight revenue increase to **₹474 crore**, though overall margins in the sector remain under pressure due to global overcapacity. Investors are advised to focus on high-margin segments like **fluorochemicals** and **agrochemicals**, which are seeing better demand recovery. Exchange Services: Record-Breaking Performance Exchange-traded services are currently the standout performers in the financial sector. **BSE Limited** shares hit an all-time high of **₹3,188** on February 10, 2026, following an exceptional earnings report. The exchange recorded a **174%** surge in consolidated net profit, reaching **₹602 crore**. This growth is driven by a massive increase in equity derivatives trading and new listings. Market sentiment is also being shaped by the primary market, with high-profile IPOs like **Fractal Analytics** (seeking **₹2,833 crore**) currently open for subscription. Meanwhile, the eventual listing of the **NSE** remains a key thematic trigger for the broader financial services category.